Why Is Moderna Stock Falling?
For questions about this article or underlying research, email help@trefis.com.
Moderna (MRNA) stock fell 7.0% on Thursday, November 12, 2026, while the S&P 500 slipped 0.3%. The drop came on the day Moderna had set for its Analyst Day, and most biotech stocks fell with it: 74 of the 79 other companies with a market value of $2 billion or more in its sub-industry ended lower. Here is what Moderna laid out that day, and how its biotech peers traded.
What Moderna Laid Out On November 12
On November 12, Moderna said it plans to reinvest in its pipeline, particularly in cancer treatments. The company is preparing to seek U.S. approval of its individualized cancer treatment, intismeran, by year-end, and executives are aiming for a 2027 launch alongside partner Merck if regulators approve it.
These plans build on what Moderna reported for the third quarter. During a November 6 call, management said patients receiving intismeran with pembrolizumab in a phase 3 melanoma trial showed a 42% lower risk of recurrence or death than those taking pembrolizumab alone. Moderna also raised $3 billion in the third quarter through a 0% convertible note, which management said strengthens its ability to invest in its cancer business.
Did Moderna Fall With Other Biotech Stocks?
Yes, though Moderna fell more than twice as far as the median company in its sub-industry, biotechnology. The median company dropped 3.0%. The weakness was wide: 21 of the 79 other companies of $2 billion or more fell 5% or more. The broader health care sector held up better, with the SPDR sector fund (XLV) down 0.6%.
Every company on Moderna’s Trefis peer list also retreated, including aTyr Pharma, down 8.3%, and Pfizer, down 2.1%. Moderna moved with its group that day, but fell further than most of it.
Where Moderna Stock Stands After The Drop
Drops of this size are not rare for Moderna. The stock had 13 falls at least as large in the prior 365 days, and the latest move at least as large in either direction was a 13.1% gain on November 4.
These swings occurred during a massive run. Moderna stock returned 776.0% over the past 12 months, against 12.2% for the S&P 500, and it returned 265.4% in the last three months alone. The shares posted their highest close of the past year, $269, on November 9, while their lowest, $22.36, came on November 20, 2025.
That run leaves the stock priced at 36.8 times its sales over the past four quarters, against 3.2 times for the S&P 500.
Moderna is expected to report its fourth-quarter 2026 results in February 2027. Its full-year 2026 revenue, measured against management’s outlook of 15% to 25% growth, is the number to watch.
Want Some Of Your Money Off This Roller Coaster?
Swings like this come with owning single stocks. The Trefis Income Solution holds 50 dividend stocks that yield about 3x the S&P 500, and in backtests it lost less than the S&P 500 in all 9 big selloffs since 2018.
Spot an error or want more like this? Tell us in 10 seconds.